NO20012567D0 - Azepinoindole derivatives, preparation and use thereof - Google Patents

Azepinoindole derivatives, preparation and use thereof

Info

Publication number
NO20012567D0
NO20012567D0 NO20012567A NO20012567A NO20012567D0 NO 20012567 D0 NO20012567 D0 NO 20012567D0 NO 20012567 A NO20012567 A NO 20012567A NO 20012567 A NO20012567 A NO 20012567A NO 20012567 D0 NO20012567 D0 NO 20012567D0
Authority
NO
Norway
Prior art keywords
preparation
azepinoindole derivatives
azepinoindole
derivatives
Prior art date
Application number
NO20012567A
Other languages
Norwegian (no)
Other versions
NO20012567L (en
Inventor
Wilfred Lubisch
Michael Kock
Thomas Hoeger
Sabine Schult
Roland Grandel
Reinhold Mueller
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/en
Priority claimed from DE10039610A external-priority patent/DE10039610A1/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20012567D0 publication Critical patent/NO20012567D0/en
Publication of NO20012567L publication Critical patent/NO20012567L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO20012567A 1999-09-28 2001-05-25 Azepinoindole derivatives, preparation and use thereof NO20012567L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (en) 1999-09-28 1999-09-28 Benzodiazepine derivatives, their production and use
DE10039610A DE10039610A1 (en) 2000-08-09 2000-08-09 Azepinoindole derivatives are PARP inhibitors and are useful for the treatment of neurodegenerative diseases, ischemia, tumor, septic shock, inflammation, rheumatic diseases, ARDS and diabetes mellitus
PCT/EP2000/009024 WO2001023390A2 (en) 1999-09-28 2000-09-15 Azepinoindole derivatives, the production and use thereof

Publications (2)

Publication Number Publication Date
NO20012567D0 true NO20012567D0 (en) 2001-05-25
NO20012567L NO20012567L (en) 2001-06-25

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012567A NO20012567L (en) 1999-09-28 2001-05-25 Azepinoindole derivatives, preparation and use thereof

Country Status (17)

Country Link
EP (1) EP1183259A2 (en)
JP (1) JP2003510328A (en)
KR (1) KR20010087401A (en)
CN (1) CN1374961A (en)
AU (1) AU1271201A (en)
BG (1) BG105650A (en)
BR (1) BR0007174A (en)
CA (1) CA2352194A1 (en)
CZ (1) CZ20012373A3 (en)
HK (1) HK1048999A1 (en)
HU (1) HUP0104917A3 (en)
IL (1) IL143349A0 (en)
NO (1) NO20012567L (en)
PL (1) PL347885A1 (en)
SK (1) SK8842001A3 (en)
TR (1) TR200101499T1 (en)
WO (1) WO2001023390A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781711B2 (en) 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
ES2354249T3 (en) 2000-12-01 2011-03-11 Eisai Inc. DERIVATIVES OF AZAFENANTRIDONA AND ITS USE AS PARP INHIBITORS.
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
CA2482806A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP2036984B1 (en) 2002-07-26 2012-02-22 BASF Plant Science GmbH Reversion of the negative selective effect of negative marker proteins as selection procedure
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
NZ547984A (en) 2003-12-01 2009-03-31 Kudos Pharm Ltd DNA damage repair inhibitors for treatment of cancer
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR20070083484A (en) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Methods for treating hepatitis c
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
EP2045327B8 (en) 2005-03-08 2012-03-14 BASF Plant Science GmbH Expression enhancing intron sequences
WO2006101937A1 (en) 2005-03-18 2006-09-28 Janssen Pharmaceutica N.V. Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (en) 2006-10-17 2008-05-31 Kudos Pharm Ltd SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS
CN101809017A (en) 2007-09-14 2010-08-18 阿斯利康(瑞典)有限公司 phthalazinone derivatives
AR070221A1 (en) 2008-01-23 2010-03-25 Astrazeneca Ab DERIVATIVES OF FTALAZINONA POLYMERASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME TO PREVENT AND / OR TREAT CANCERIGENE TUMORS, ISCHEMICAL INJURIES AND OTHER ASSOCIATED DISEASES.
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
PT2346495T (en) 2008-10-07 2016-11-11 Astrazeneca Uk Ltd Pharmaceutical formulation 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
AU2010325549B2 (en) 2009-11-27 2017-04-20 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
CA2781835A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
CN102686726B (en) 2009-11-27 2015-12-16 巴斯夫植物科学有限公司 Chimeric endonuclease and uses thereof
EP2575815A4 (en) 2010-06-04 2013-12-25 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
ES2879434T3 (en) 2015-07-23 2021-11-22 Inst Curie Use of a combination of Dbait molecule and PARP inhibitors for cancer treatment
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
JP7264489B2 (en) * 2017-05-24 2023-04-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Radiolabeled fluorescent PARP inhibitors for imaging and radiotherapy
KR20200130856A (en) 2018-03-13 2020-11-20 옹쎄오 Debate molecule for resistance acquired in cancer treatment
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3919495A4 (en) * 2019-02-02 2022-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analogue as parp inhibitor
WO2021018298A1 (en) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 Indolo-seven-membered acyloxime compounds as parp inhibitors
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4190790A1 (en) * 2020-07-31 2023-06-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011644A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU781711B2 (en) * 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
ECSP003637A (en) * 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES

Also Published As

Publication number Publication date
WO2001023390A3 (en) 2001-12-27
CZ20012373A3 (en) 2002-05-15
HUP0104917A3 (en) 2002-12-28
HK1048999A1 (en) 2003-04-25
SK8842001A3 (en) 2002-01-07
EP1183259A2 (en) 2002-03-06
IL143349A0 (en) 2002-04-21
PL347885A1 (en) 2002-04-22
BG105650A (en) 2002-02-28
WO2001023390A2 (en) 2001-04-05
CN1374961A (en) 2002-10-16
AU1271201A (en) 2001-04-30
JP2003510328A (en) 2003-03-18
KR20010087401A (en) 2001-09-15
NO20012567L (en) 2001-06-25
TR200101499T1 (en) 2002-09-23
HUP0104917A2 (en) 2002-04-29
BR0007174A (en) 2001-09-04
CA2352194A1 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
NO20012567D0 (en) Azepinoindole derivatives, preparation and use thereof
NO20021379D0 (en) Benzodiazepine derivatives, preparation and use thereof
NO20021449D0 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
NO20015156L (en) 5-pyridyl-1,3-azole compounds, their preparation and use
IS6385A (en) New uses and new N-azabicyclo-amide derivatives
NO20014603L (en) Tienopyrimidine Compounds, Their Preparation and Use
IS6661A (en) Benzimidazole derivatives, their preparation and therapeutic use
DK1161434T3 (en) Pyridopyranoazepine derivatives, their preparation and therapeutic use
DK1073672T3 (en) Antipicornaviral compounds, their preparation and use
IS6420A (en) Presents Phenyl-piperazine derivatives, their preparation and use
NO20031838D0 (en) Benzocazine derivatives, their preparation and use
DK1043307T3 (en) 3-Amino-3-arylpropan-1-ol derivatives, their preparation and use
DK1417189T3 (en) Acylaminothiazole derivatives, preparation and therapeutic use thereof
DK1334106T3 (en) Imidazole derivatives, their preparation methods and their use
NO20020156L (en) Titanium derived compounds, their preparation and their use
DK1025100T3 (en) 3-substituted tetrahydropyridopyrimidinone derivatives, their preparation and their use
DE60032898D1 (en) ARYLTHIAZOLIDEINDION AND ARYLOXAZOLIDINE DERIVATIVES
NO20024107L (en) Tienopyridine derivatives, their preparation and use
NO20006479D0 (en) Tienopyridine compounds, their preparation and use
NO20001782D0 (en) 3-Amino-3-arylpropan-1-ol derivatives, their preparation and use
NO20000066D0 (en) 6-Pyrrolidin-2-ylpyrindine Derivatives, their Preparation and their Pharmaceutical Use
NO996156L (en) Substituted cycloheptans, their preparation and use
IS6391A (en) 2-Arylquinoline derivatives, preparation and therapeutic use thereof
DK1127052T3 (en) Substituted 2-phenylbenzimidazoles, preparation and use thereof
DK1177196T3 (en) Heter Garyldiazabicycloalkanes, their preparation and use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application